Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIM AIM ImmunoTech	$2.67 +1.5%	$7.47	$2.46 ▼ $39.95	$2.04M	0.88	66,662 shs	71,068 shs
GNCAQ Genocea Biosciences		$0.00	$0.00 ▼ $0.00	$6K	1.74	1,863 shs	N/A
PTE PolarityTE		$0.37	$0.20 ▼ $1.90	$1.78M	1.15	249,591 shs	8.50 million shs
SRNE Sorrento Therapeutics	$0.00 +33.3%	$0.00	$0.00 ▼ $0.02	$1.10M	0.85	106,905 shs	528,669 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIM AIM ImmunoTech	+1.54%	-9.93%	-71.33%	-71.23%	-90.11%
GNCAQ Genocea Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
PTE PolarityTE	0.00%	0.00%	0.00%	0.00%	0.00%
SRNE Sorrento Therapeutics	-25.00%	-34.78%	-37.50%	-77.61%	-76.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIM AIM ImmunoTech	1.0572 of 5 stars	3.5	0.0	0.0	0.0	1.1	0.0	0.0
GNCAQ Genocea Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PTE PolarityTE	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SRNE Sorrento Therapeutics	0.7596 of 5 stars	0.0	2.0	0.0	4.3	0.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIM AIM ImmunoTech	3.00	Buy	$275.00	10,199.63% Upside
GNCAQ Genocea Biosciences	0.00	N/A	N/A	N/A
PTE PolarityTE	0.00	N/A	N/A	N/A
SRNE Sorrento Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIM AIM ImmunoTech	$146K	13.97	N/A	N/A	$0.20 per share	13.35
GNCAQ Genocea Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
PTE PolarityTE	$810K	0.00	N/A	N/A	$2.30 per share	0.00
SRNE Sorrento Therapeutics	$60.32M	0.02	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIM AIM ImmunoTech	-$28.96M	-$24.00	N/A	N/A	N/A	-12,594.21%	-421.73%	-147.54%	N/A
GNCAQ Genocea Biosciences	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
PTE PolarityTE	-$7.83M	-$3.28	N/A	N/A	N/A	N/A	-106.08%	-76.91%	N/A
SRNE Sorrento Therapeutics	-$572.84M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIM AIM ImmunoTech	N/A	N/A	N/A	N/A	N/A
GNCAQ Genocea Biosciences	N/A	N/A	N/A	N/A	N/A
PTE PolarityTE	N/A	N/A	N/A	N/A	N/A
SRNE Sorrento Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIM AIM ImmunoTech	0.05	0.75	0.75
GNCAQ Genocea Biosciences	N/A	N/A	N/A
PTE PolarityTE	N/A	4.11	4.11
SRNE Sorrento Therapeutics	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIM AIM ImmunoTech	12.02%
GNCAQ Genocea Biosciences	N/A
PTE PolarityTE	11.75%
SRNE Sorrento Therapeutics	0.02%

Insider Ownership

Company	Insider Ownership
AIM AIM ImmunoTech	0.02%
GNCAQ Genocea Biosciences	1.61%
PTE PolarityTE	5.40%
SRNE Sorrento Therapeutics	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIM AIM ImmunoTech	20	764,000	68.74 million	Not Optionable
GNCAQ Genocea Biosciences	70	58.73 million	N/A	Not Optionable
PTE PolarityTE	42	7.38 million	6.98 million	Optionable
SRNE Sorrento Therapeutics	800	551.28 million	536.95 million	No Data

PTE, AIM, SRNE, and GNCAQ Headlines

Recent News About These Companies

Sorrento Therapeutics Inc (SRNE) - Investing.com

July 3, 2025 | investing.com

SRNE Sorrento Therapeutics, Inc. - Seeking Alpha

June 29, 2025 | seekingalpha.com

Sorrento Therapeutics Stock Price, Quotes and Forecasts | OTC:SRNE | Benzinga

April 19, 2025 | benzinga.com

Sorrento Shareholders Lose Discovery Bid Over Judge Relationship

March 28, 2025 | news.bloomberglaw.comN

Scilex says bankruptcy court extends lockup period on shares of Scilex dividend

January 31, 2025 | markets.businessinsider.com

DSI Introduces Westbury Sorrento Aluminum Railing with Bold Distinctive Mesh Stainless Steel Infills

October 24, 2024 | newsfilecorp.comN

Sorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO says

August 20, 2024 | msn.com

Sorrento Resources to Sell Three Newfoundland Properties to Gold Hunter

May 29, 2024 | newsfilecorp.comN

Sorrento Therapeutics Inc (SRNE)

May 25, 2024 | investing.com

Sorrento Resources Announces Appointment of Alex Bugden as a Director and Qualified Person

May 8, 2024 | newsfilecorp.comN

DSI Introduces Westbury(R) Sorrento Aluminum and Stainless Steel Mesh Railing

May 1, 2024 | newsfilecorp.comN

Sorrento Therapeutics Inc SRNE

April 26, 2024 | morningstar.comM

Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks

March 27, 2024 | news.bloomberglaw.comN

Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks

March 27, 2024 | news.bloomberglaw.comN

Sorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)

March 12, 2024 | news.bloomberglaw.comN

Judge Declines to Dismiss Sorrento Therapeutics Bankruptcy Case

March 12, 2024 | wsj.com

Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

February 27, 2024 | tmcnet.com

Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

February 27, 2024 | businesswire.com

Sorrento Therapeutics

February 7, 2024 | pharmaphorum.comP

5 Sanders Cove, Sorrento WA 6020

January 18, 2024 | domain.com.auD

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PTE, AIM, SRNE, and GNCAQ Company Descriptions

AIM ImmunoTech NYSE:AIM

$2.67 +0.04 (+1.52%)

Closing price 04:00 PM Eastern

Extended Trading

$2.64 -0.02 (-0.94%)

As of 07:51 PM Eastern

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Genocea Biosciences NASDAQ:GNCAQ

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. The plan was later approved as Chapter 11 liquidation on May 11, 2023.

PolarityTE NASDAQ:PTE

PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

Sorrento Therapeutics NASDAQ:SRNE

$0.0020 +0.00 (+33.33%)

As of 03:20 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time